Danaher (DHR) Liabilities from Discontinued Operations (2014 - 2022)
Danaher (DHR) posted Liabilities from Discontinued Operations of $1.1 billion for Q4 2022, up 86.28% on a QoQ basis from $605.0 million in Q4 2018.
Analysis
Danaher (DHR) Liabilities from Discontinued Operations (2014 - 2022) Analysis & Trends
Danaher has reported Liabilities from Discontinued Operations for 4 years, with the latest figure at $1.1 billion in Q4 2022.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $1.1 billion in Q4 2022; TTM through Dec 2022 was $1.1 billion, a N/A change from a year earlier, with the FY2022 full-year figure at $1.1 billion, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $1.1 billion for Q4 2022 at Danaher, up from $605.0 million in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was $1.1 billion in Q4 2022, with the low at $605.0 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 1.13 Bn |
| Dec 31, 2018 | 605.00 Mn |
| Dec 31, 2015 | 1.84 Bn |
| Oct 2, 2015 | 42.40 Mn |
| Dec 31, 2014 | 467.60 Mn |